Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


NeuBase Therapeutics Reports Positive Preclinical In Vivo Data For PATrOL-Enabled Anti-Gene For Treatment Of Myotonic Dystrophy Type 1


Benzinga | Dec 16, 2020 06:52AM EST

NeuBase Therapeutics Reports Positive Preclinical In Vivo Data For PATrOL-Enabled Anti-Gene For Treatment Of Myotonic Dystrophy Type 1

In vivo data after single-dose IV administration demonstrate engagement with DMPK mRNA and broad rescue of mis-splicing across key transcripts



Findings provide support for hypothesized mechanism of action of anti-gene, which is designed to not degrade the DMPK transcript

Data further validate the potential of the PATrOL(tm) platform to develop highly targeted therapies that increase, decrease or change causal protein function

NeuBase management to hold conference call and webcast today, December 16, at 8:00 a.m. EST

PITTSBURGH, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, today announced positive in vitro and in vivo preclinical data for its PATrOL(tm)-enabled anti-gene therapies for the treatment of myotonic dystrophy type 1 (DM1). These new data show that PATrOL-enabled Compound A can rapidly resolve mis-splicing without negatively impacting DMPK protein levels. They also support the potential of NeuBase's anti-gene approach to comprehensively treat the underlying cause of DM1.

"Despite the fact that the genetic basis of DM1 is well understood today, there is still an urgent need to find the first genetically-targeted, disease-modifying treatment option for affected patients," said Curt Bradshaw, Ph.D., Chief Scientific Officer of NeuBase. "DM1 is caused by a genetic mutation in the DMPK gene leading to mis-splicing of a broad spectrum of genes and DMPK protein insufficiency. A treatment option that addresses mis-splicing while retaining functional DMPK protein levels may be key to treating all aspects of DM1."

Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, added, "Using our proprietary PATrOL platform, we have designed a first-in-class anti-gene candidate that selectively binds mutant DMPK mRNA and opens its hairpin secondary structure, as opposed to a mechanism of action that explicitly degrades the mutant and wild-type transcripts indiscriminately, making it a unique option for the treatment of DM1. These in vitro and in vivo data both support our hypothesized mechanism of action and demonstrate rapid and broad resolution of the mis-splicing that is the primary cause of DM1.

"This is the second set of positive data that we've announced in 2020 for our PATrOL-enabled therapies, which we believe serves as proof of concept that further validates our technologic foundation. With a single unified platform, we believe we can increase, decrease or change protein function of potentially any nucleic acid target, unique among genetic medicine approaches. We are excited by the progress we have made and look forward to providing additional updates on our platform and pipeline of programs at an R&D day in the first half of 2021."

In vitro data highlights in DM1 patient-derived fibroblasts:

? Compound A traffics to the nucleus, engages and normalizes DMPK mRNA. Compound A rescues mis-splicing of two key DM1 dysregulated transcripts (? MBNL1 and MBNL2) within two days after initial treatment. Notably, induction of rescue continues to improve through day 9, the latest time point analyzed. ? Compound A significantly induces broad correction of global exon inclusion levels of mis-spliced transcripts. -o Statistically significant improvement in global splicing as measured by the human differential splice inclusion (hDSI) statistic. More than 175 dysregulated human transcripts achieved statistically -o significant improvement in splicing, many with completely normalized exon usage.? DMPK protein levels remain unchanged 5 days after a single Compound A dose, supporting the hypothesized mechanism of action maintaining DMPK.

In vivo data highlights in the HSALR transgenic mouse model of DM1 that expresses high levels of mutant CUG-repeat-containing mRNA (HSA) in skeletal muscle:



A single intravenous (IV) injection of 29 mg/kg of Compound A traffics to the? nucleus and engages HSA mRNA within 24 hours in tibialis anterior (TA) skeletal muscle. A single intravenous (IV) injection of Compound A significantly induces broad? correction of global exon inclusion levels of mis-spliced transcripts in HSALR TA skeletal muscle at day 13. ? Statistically significant improvement in global splicing as measured by the murine differential splice inclusion (mDSI) statistic. More than 50 unique dysregulated murine transcripts achieved -o statistically significant improvement in splicing post-treatment, with many achieving complete normalization of appropriate exon usage.? Compound A was well tolerated after single dose administration at the dose demonstrating activity in vivo.

DM1 is a rare, autosomal dominant repeat expansion disorder characterized by progressive muscle wasting and weakness. It also affects the central nervous system (CNS) and heart. DM1 is caused by CTG nucleic acid repeats in the DMPK gene that produce a hairpin structure in the transcribed DMPK mRNA. The hairpin structure sequesters critical splice regulators and results in the mis-splicing of multiple gene transcripts. Furthermore, the binding of splice regulators traps the mutant DMPK mRNA in the nucleus, resulting in DMPK protein haploinsufficiency, or half the level of protein that is needed for normal function, which is thought to exacerbate the CNS and cardiac symptoms that are characteristic of DM1 (as knock-out mice for Dmpk show both severe cardiac conduction defects as well as issues with neuronal cytoskeletal remodeling manifesting in aberrant long-term potentiation). The prevalence of DM1 is >5/100,000 in the general population. There are currently no approved treatments for DM1.






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC